Syqe Medical, along with Novachem, has announced the approval of the SyqeAir Inhaler by the Therapeutic Goods Administration in Australia.
Novachem is Syqe Medical’s sponsor and distribution partner in Australia.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
SyqeAir has also been included in the Australian Register of Therapeutic Goods (ARTG). It is claimed to be the first and only metered-dose cannabis inhaler to receive ARTG approval.
This medical device has been designed for administering low, metered and consistent doses of medicinal cannabis through inhalation, aerosolised from dried milled flowers.
Suitable for managed healthcare settings and home use, the device features an inhaler and a pre-loaded cartridge that contains 60 uniform doses of pharmaceutical-grade, standardised raw cannabis flowers.
SyqeAir CEO Hagit Kamin said: “Receiving ARTG approval in Australia is a significant achievement for our company.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“We are excited to collaborate with healthcare professionals and organisations in Australia to expand access to the SyqeAir Inhaler, enabling patients to benefit from reliable and consistent medicinal cannabis treatment.”
The cannabis in the cartridges is grown according to EU-GMP regulations by Dutch company Bedrocan.
Three clinical trials and real-world evidence publications have confirmed the effectiveness and safety of the device.
Novachem medical products manager Andrew Heath said: “The SyqeAir Inhaler represents a significant step forward in the medicinal cannabis industry, offering patients and healthcare professionals a safer, consistent and easy-to-use delivery system.”
Recently, Syqe has entered a strategic agreement with the Israeli Ministry of Defense to deliver its inhaler to all its veterans experiencing chronic pain and post-traumatic stress disorder who require medicinal cannabis treatment.
